Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.

Scientists have developed a blood test for Alzheimer’s disease that can help diagnose the neurodegenerative disease while ...

It wasn't that long ago that the only way to test for Alzheimer's disease was to perform an autopsy on someone who had been ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

W ith two new treatments for Alzheimer’s disease approved in recent years, there’s growing hope for people at risk of the ...

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...